“…Mesalaminerelated nephrotoxicity can be a serious complication and delays in diagnosis and treatment discontinuation can lead to end-stage renal disease [ 6 , 9 , 10 ]. Moreover, nephrotoxicity has also been reported with anti-tumor necrosis factors agents (anti-TNF) and with vedolizumab [11][12][13][14] . Finally, kidney-related extra-intestinal manifestations (EIMs) (e.g., nephrolithiasis, tubulointerstitial nephritis, glomerulonephritis or amyloidosis) can also occur along IBD course independently to the associated treatments [15][16][17] .…”